AOD 9604 and Retatrutide: What the Evidence Says

There is no clinical evidence that stacking AOD-9604 and retatrutide is safe or effective. AOD-9604 is a synthetic growth hormone fragment sold as a research peptide, and retatrutide is an investigational triple-receptor obesity drug still completing phase 3 trials. Neither compound is FDA-approved for human use, and no published study has tested them together.

That has not stopped people from searching for the combination online. This guide explains what each compound does, what human data actually exists, and where the real safety questions sit.

What Is AOD-9604?

AOD-9604 is a modified fragment of human growth hormone, specifically the C-terminal portion known as amino acids 176–191. Researchers designed it to isolate the fat-metabolizing effects of growth hormone without triggering growth, insulin resistance, or the other systemic effects of full HGH.

In lab and animal studies, AOD-9604 stimulates lipolysis, the breakdown of stored fat, and inhibits lipogenesis, the formation of new fat. Early human trials in the 2000s examined it for obesity, but results were modest and the drug never advanced to phase 3 testing or FDA review.

Today AOD-9604 is sold online as a research peptide. A complete picture of aod-9604 benefits and side effects is hard to confirm because most current use happens outside controlled clinical trials.

What Is Retatrutide?

Retatrutide (LY3437943) is a single molecule that activates three receptors at once: GLP-1, GIP, and glucagon. That triple mechanism separates it from earlier weight-loss drugs such as semaglutide, which targets GLP-1 only, and tirzepatide, which targets GIP and GLP-1.

In a 2023 phase 2 trial published in the New England Journal of Medicine, adults with obesity who received 12 mg of retatrutide weekly lost an average of roughly 24% of their body weight over 48 weeks. That is a larger average reduction than any approved obesity medication has shown in a comparable trial.

Retatrutide is still investigational. Eli Lilly is running the phase 3 TRIUMPH program, and the FDA has not approved the drug for any indication.

AOD-9604 vs Retatrutide: Key Differences

These two compounds are not interchangeable, and they do not belong to the same drug class. The table below summarizes the main differences.

Another research peptide, MOTS-c, is often discussed alongside AOD-9604 because both are marketed for metabolic effects. Researchers comparing aod 9604 vs mots-c are mainly looking at mechanism: MOTS-c is a mitochondrial-derived peptide studied for insulin sensitivity, while AOD-9604 is studied for fat breakdown.

Is Stacking AOD-9604 and Retatrutide Safe?

No human trial has combined AOD-9604 and retatrutide. That means there is no dosing data, no safety data, and no evidence that the two produce better results together than either one alone.

Retatrutide already carries a substantial side-effect profile on its own. In phase 2 trials, common adverse events included nausea, vomiting, diarrhea, and constipation, and the drug raised resting heart rate in a dose-dependent way. Adding an unapproved growth hormone fragment could theoretically compound metabolic stress, but nobody has measured that risk.

Key conclusion: There is no clinical evidence that AOD-9604 and retatrutide are safe or effective when stacked.

Anyone using either compound is doing so outside FDA oversight. If you take a prescribed GLP-1 or GIP medication and are considering a research peptide on top of it, speak with a healthcare professional first.

What to Know About Dosing and Sourcing

AOD-9604 dosing is not established by regulators. In older research protocols, participants typically received subcutaneous injections once daily, which is why people ask how often do you take aod 9604. Retatrutide is dosed once weekly in trials, but those doses were determined under close medical supervision.

Online vendors often sell AOD-9604 in 5 mg vials, which is the origin of the aod-9604 5mg dosage question. A 5 mg vial is a quantity of powder, not a dose. Turning it into an injectable solution requires bacteriostatic water, sterile technique, and accurate syringe measurements.

People who search to buy aod-9604 peptide often land on gray-market sites with no third-party purity testing, no sterility assurance, and no dosing guidance. Retatrutide has the same problem: legitimate supply is limited to clinical trials, so most online “retatrutide” is unverified.

Gelling during reconstitution is a known complaint with some peptides. It usually signals poor solubility, the wrong diluent, or degraded product. Do not inject a solution that looks cloudy, clumpy, or gelatinous.

What the Evidence Says So Far

• AOD-9604 has early human trial data suggesting modest fat loss, but no phase 3 trial and no FDA approval.
• Retatrutide has strong phase 2 data showing large weight reductions, but it remains investigational.
• No study has tested AOD-9604 and retatrutide together in humans.
• Both compounds are widely counterfeited or sold as unverified research chemicals online.

Bottom Line

AOD-9604 and retatrutide are two very different compounds at very different stages of development. Retatrutide is a promising investigational obesity drug with real phase 2 data behind it, while AOD-9604 is an older peptide that never cleared regulatory review.

Stacking them is an experiment with no supporting evidence and significant unknowns. If you have obesity or metabolic concerns, the safer path is to ask a healthcare professional about FDA-approved options or enrollment in a clinical trial.